Miranda Stratton
Miranda Stratton has a total of 8 co-authors. Here are the top co-authors by number of shared publications:
- Kelly K. Houck
Veteran Health Indiana Indianapolis Indiana USA
3 shared publications Jeremy Hooker
Roudebush VA Med Ctr, Pain & Palliat Care, Indianapolis, IN USA
2 shared publications- Mallory Alexander
Roudebush VA Med Ctr, Veteran Hlth Indiana, Indianapolis, IN USA
2 shared publications Morgan Huh
OrthoIndy Hosp, Indianapolis, IN USA
2 shared publications- Amanda P. Ifeachor
Clinical Pharmacy Practitioner – Ambulatory Care (Gastrointestinal/Hepatitis C Virus Clinics), Veteran Health Indiana, Indianapolis, Indiana
1 shared publication - Elayne D. Ansara
Clinical Pharmacy Practitioner – Mental Health, Veteran Health Indiana, Indianapolis, Indiana
1 shared publication
Latest Publications
- 10 August 2024
- Published by Elsevier in Journal of the American Pharmacists Association
- Vol. 64 (4) , 102168
Reprint of: Assessment of a naloxone distribution plan in a veteran population who experienced an opioid-related overdose event
- 10 August 2024
- Published by Elsevier in Journal of the American Pharmacists Association
- Vol. 64 (4) , 102168
Reprint of: Assessment of a naloxone distribution plan in a veteran population who experienced an opioid-related overdose event
- 25 December 2023
- Published by Elsevier in Journal of the American Pharmacists Association
- Vol. 64 (3) , 101999
Assessment of a naloxone distribution plan in a veteran population who experienced an opioid-related overdose event
- 25 December 2023
- Published by Elsevier in Journal of the American Pharmacists Association
- Vol. 64 (3) , 101999
Assessment of a naloxone distribution plan in a veteran population who experienced an opioid-related overdose event
- Open Access
- 1 June 2022
- Published by American Association of Psychiatric Pharmacists (AAPP) in Mental Health Clinician
- Vol. 12 (3) , 181-186
Assessment of hepatitis C monitoring adherence after viral eradication in veterans with substance use to improve care and surveil reinfection
Introduction: Hepatitis C virus (HCV) incidence rates are rising for patients with substance use and/or SUDs. Guidelines provide monitoring recommendations to ensure remission after successful treatment. The study's objective was to identify gaps in follow-up for patients with documented substance use and/or SUD through assessment of adherence to guideline-recommended HCV RNA lab 12 months post-treatment. Methods: Patients treated for HCV through the Veteran Health Indiana Hepatitis C Pharmacy Clinic were retrospectively evaluated. Subjects were categorized based on the provider assigned for follow-up care after 12-week sustained virologic response (SVR12) labs (primary care provider [PCP] or HCV provider). The primary outcome was HCV RNA obtained 11 to 13 months post-treatment. Secondary outcomes were HCV RNA detected post-treatment, substance use, engagement in substance use treatment, and engagement with social work. Results: Two hundred forty-one patients were included in the HCV provider cohort and 139 in the PCP cohort. Forty-one patients did not have a specified clinic for follow-up treatment, and 20 patients did not achieve SVR12. Sixty-one patients (28%) in the HCV provider cohort completed a 12-month HCV RNA within 11 to 13 months post-treatment vs 15 patients (11%) in the PCP cohort (P ≤ .01). One patient had HCV RNA detected post-treatment. Discussion: This study reveals inadequate HCV post-treatment follow-up for patients with substance use and/or SUD. SUD is a chronic disease that requires continued monitoring to prevent complications. Further studies are needed to identify reinfection rates and improvements of care in this population.
- 1 June 2022
- Published by American Association of Psychiatric Pharmacists (AAPP) in Mental Health Clinician
- Vol. 12 (3) , 181-186
Open AccessAssessment of hepatitis C monitoring adherence after viral eradication in veterans with substance use to improve care and surveil reinfection
Introduction: Hepatitis C virus (HCV) incidence rates are rising for patients with substance use and/or SUDs. Guidelines provide monitoring recommendations to ensure remission after successful treatment. The study's objective was to identify gaps in follow-up for patients with documented substance use and/or SUD through assessment of adherence to guideline-recommended HCV RNA lab 12 months post-treatment. Methods: Patients treated for HCV through the Veteran Health Indiana Hepatitis C Pharmacy Clinic were retrospectively evaluated. Subjects were categorized based on the provider assigned for follow-up care after 12-week sustained virologic response (SVR12) labs (primary care provider [PCP] or HCV provider). The primary outcome was HCV RNA obtained 11 to 13 months post-treatment. Secondary outcomes were HCV RNA detected post-treatment, substance use, engagement in substance use treatment, and engagement with social work. Results: Two hundred forty-one patients were included in the HCV provider cohort and 139 in the PCP cohort. Forty-one patients did not have a specified clinic for follow-up treatment, and 20 patients did not achieve SVR12. Sixty-one patients (28%) in the HCV provider cohort completed a 12-month HCV RNA within 11 to 13 months post-treatment vs 15 patients (11%) in the PCP cohort (P ≤ .01). One patient had HCV RNA detected post-treatment. Discussion: This study reveals inadequate HCV post-treatment follow-up for patients with substance use and/or SUD. SUD is a chronic disease that requires continued monitoring to prevent complications. Further studies are needed to identify reinfection rates and improvements of care in this population.